<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634839</url>
  </required_header>
  <id_info>
    <org_study_id>2000023077-1</org_study_id>
    <nct_id>NCT03634839</nct_id>
  </id_info>
  <brief_title>Effects of E-cigarette Flavors on Youth TCORS 2.0</brief_title>
  <official_title>Effects of E-cigarette Flavors on Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an examination of the influence of sweet and cooling flavors on the appeal and
      abuse potential of nicotine-containing e-cigarettes among susceptible youth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Researchers will examine the influence of sweet and cooling flavors on the appeal and abuse
      potential of nicotine-containing e-cigarettes among susceptible youth. Participants will rate
      the flavor intensity, coolness, sweetness, and irritation experienced using validated rating
      scales. Sixty youth (16-20 years of age) who have experimented with e-cigarettes and are not
      regular users will participate in 3 laboratory sessions, separated by at least 24 hrs. They
      will be randomized to receive 1 of 3 nicotine concentrations (0, 3 or 12 mg/ml) during each
      of the three sessions; during each session they will be exposed, in random order, to sweet
      (strawberry, vanilla) and tobacco flavors, with and without menthol, combined with the
      assigned session nicotine concentration.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change score in liking/wanting of e-cigarette</measure>
    <time_frame>Baseline (+10 minutes) to end of lab session (+40 minutes)</time_frame>
    <description>The Labeled Hedonic Scale (LHS; Lim et al., 2009) will be used to ask about liking and wanting of the e-cigarette (one item VAS scale with ratings from most disliked sensation imaginable to most liked sensation imaginable with higher values indicating greater liking)</description>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nicotine Use Disorder</condition>
  <arm_group>
    <arm_group_label>Nicotine 0 mg, Sweet non-menthol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nicotine 0 mg combined with sweet non-menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 3 mg, Sweet non-menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 3 mg combined with sweet non-menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 12 mg, Sweet non-menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 12 mg combined with sweet non-menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 0 mg, Sweet menthol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nicotine 0 mg combined with sweet menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 3 mg, Sweet menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 3 mg combined with sweet menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 12 mg, Sweet menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 12 mg combined with sweet menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 0 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nicotine 0 mg combined with tobacco non-menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 3 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 3 mg combined with tobacco non-menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 12 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 12 mg combined with tobacco non-menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 0 mg, Tobacco menthol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nicotine 0 mg with tobacco menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 3 mg, Tobacco menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 3 mg combined with tobacco menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine 12 mg, Tobacco menthol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine 12 mg combined with tobacco menthol flavor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flavor</intervention_name>
    <description>Flavor of e-liquid - sweet or tobacco</description>
    <arm_group_label>Nicotine 0 mg, Sweet menthol</arm_group_label>
    <arm_group_label>Nicotine 0 mg, Sweet non-menthol</arm_group_label>
    <arm_group_label>Nicotine 0 mg, Tobacco menthol</arm_group_label>
    <arm_group_label>Nicotine 0 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Sweet menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Sweet non-menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Tobacco menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Sweet menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Sweet non-menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Tobacco menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Tobacco non-menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Nicotine level (0, 3, or 12 mg)</description>
    <arm_group_label>Nicotine 0 mg, Sweet menthol</arm_group_label>
    <arm_group_label>Nicotine 0 mg, Sweet non-menthol</arm_group_label>
    <arm_group_label>Nicotine 0 mg, Tobacco menthol</arm_group_label>
    <arm_group_label>Nicotine 0 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Sweet menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Sweet non-menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Tobacco menthol</arm_group_label>
    <arm_group_label>Nicotine 12 mg, Tobacco non-menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Sweet menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Sweet non-menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Tobacco menthol</arm_group_label>
    <arm_group_label>Nicotine 3 mg, Tobacco non-menthol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 16-20 years

          -  Able to read and write

          -  Tried e-cigs at least once but no more than 10 times in lifetime

          -  No past month use of e-cigarettes

        Exclusion Criteria:

          -  Daily use of other drugs including prescribed psychoactive drugs

          -  Any significant current medical or psychiatric condition

          -  Known hypersensitivity to propylene glycol

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alissa Goldberg, LMSW</last_name>
    <phone>203-974-7809</phone>
    <email>alissa.goldberg@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asti Jackson, PhD</last_name>
    <phone>203-974-7598</phone>
    <email>asti.jackson@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CMHC, Substance Abuse Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alissa Goldberg, LMSW</last_name>
      <phone>203-974-7809</phone>
      <email>alissa.goldberg@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Asti Jackson, PhD</last_name>
      <phone>203-974-7598</phone>
      <email>asti.jackson@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

